Destiny Pharma Limited - In Liquidation Email Format

Biotechnology ResearchEngland, United Kingdom2-10 Employees

Destiny Pharma Limited is a biotechnology research company based in Science Park Square, Brighton, England, United Kingdom. It operates as a clinical-stage biotechnology company focused on developing novel medicines to prevent life-threatening infections, including microbiome-based biotherapeutics and XF drug assets. Its pipeline includes NTCD-M3, a Phase 3 ready treatment for preventing recurrence of Clostridioides difficile infection, and XF-73 nasal gel, which has completed a positive Phase 2b trial for preventing post-surgical staphylococcal hospital infections including MRSA. Destiny Pharma has pursued collaborations and licensing arrangements, including a Sebela Pharmaceuticals deal for NTCD-M3 and a dermal XR-73 program with China Medical Systems. The company is currently in liquidation with joint administrators and later joint liquidators appointed, and it employs between 2 and 10 people.

Sign up for free to view info

Company overview Employee directory